{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:59:40Z","timestamp":1787169580066,"version":"build-2736575974"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The efficacy of integrase strand transfer inhibitors (INSTIs) among adults with HIV is well-established, though adverse effects, particularly weight gain, are common. Comparable data for treatment-experienced adolescents and young adults with perinatally-acquired HIV (AYAPHIV) are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AYAPHIV in the US-based Pediatric HIV\/AIDS Cohort Study who switched to bictegravir (BIC), dolutegravir (DTG), elvitegravir (EVG), or raltegravir (RAL) from any prior regimen were eligible. Using mixed-effects models, viral load, CD4 count, weight, and body mass index were described through 2 years after switch for each INSTI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 556 AYAPHIV, there were 167 switches to BIC, 282 to DTG, 189 to EVG, and 151 to RAL. Viral suppression (&amp;lt;200\u2005copies\/mL) at 1 and 2 years after switch was 74% and 69% for BIC, 62% and 60% for DTG, 76% and 68% for EVG, and 58% and 52% for RAL. Mean CD4 counts were above 500\u2005cells\/mm3 after switch through 2 years for all INSTIs. Average weight gain in the first year after switch to BIC, DTG, EVG, and RAL was 0.2, 2.5, 3.8, and \u22120.2 kilograms for females and 2.3, 4.8, 2.9, and 2.6 kilograms for males. Among previously underweight\/healthy individuals, 13%, 18%, 36%, and 12% of females and 6%, 8%, 12%, and 11% of males switching to BIC, DTG, EVG, and RAL were overweight\/obese by 2 years after switch.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Individual INSTI-based regimens among treatment-experienced AYAPHIV had moderate effectiveness with respect to viral suppression. Continued average weight gain across INSTIs raises concerns about long-term cardiometabolic sequalae.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf538","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:02:53Z","timestamp":1758888173000},"page":"e78-e88","source":"Crossref","is-referenced-by-count":1,"title":["Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0002-681X","authenticated-orcid":false,"given":"Kunjal","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]},{"name":"Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Jaramillo-Underwood","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Karalius","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzy-Jyun","family":"Yao","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell B","family":"Van Dyke","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Tulane University School of Medicine , New Orleans, Louisiana ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2671-0903","authenticated-orcid":false,"given":"Ayesha","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Florida College of Medicine , Jacksonville, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1894-6040","authenticated-orcid":false,"given":"Jennifer","family":"Jao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L","family":"Agwu","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Johns Hopkins School of Medicine , Baltimore, Maryland ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Pediatric HIV\/AIDS Cohort Study (PHACS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Hernandez-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Jao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R","family":"Seage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Van Dyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Siminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Wolbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela (Lela)","family":"Lartey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Malee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Buschur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chivon","family":"McMullen-Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murli","family":"Purswani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboobullah Mirza","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Gaye","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Bernegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Garvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra K","family":"Burchett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M","family":"Salois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wiznia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Burey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arry","family":"Dieudonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Surowiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet S","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taesha","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitzie","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Odero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heida","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Silio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medea","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sirois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A","family":"Spector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Loughran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"McEnvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Caffroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anai","family":"Cuadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2026020904065362000_ciaf538-B1","doi-asserted-by":"crossref","first-page":"e127\u201336","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"2026020904065362000_ciaf538-B2","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus Abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"2026020904065362000_ciaf538-B3","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"2026020904065362000_ciaf538-B4","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet"},{"key":"2026020904065362000_ciaf538-B5","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"2026020904065362000_ciaf538-B6","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2026020904065362000_ciaf538-B7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijantimicag.2019.08.008","article-title":"Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors","volume":"54","author":"Yang","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2026020904065362000_ciaf538-B8","doi-asserted-by":"crossref","first-page":"e347-56","DOI":"10.1016\/S2352-3018(18)30091-2","article-title":"Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"key":"2026020904065362000_ciaf538-B9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","article-title":"Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial","volume":"14","author":"Arribas","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2026020904065362000_ciaf538-B10","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir-based regimen versus continuation of a lopinavir\u2013ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"key":"2026020904065362000_ciaf538-B11","first-page":"80","article-title":"STRIIVING: switching to Abacavir\/dolutegravir\/lamivudine fixed dose combination (ABC\/DTG\/3TC FDC) from a PI, INI or NNRTI based regimen maintains HIV suppression at week 48","volume":"19","author":"Lake","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"2026020904065362000_ciaf538-B12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"2026020904065362000_ciaf538-B13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"Molina","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"2026020904065362000_ciaf538-B14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/QAD.0000000000002194","article-title":"Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting","volume":"33","author":"Davy-Mendez","year":"2019","journal-title":"AIDS"},{"issue":"7)","key":"2026020904065362000_ciaf538-B15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/hiv.13262","article-title":"Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe","volume":"23","author":"Rossetti","year":"2022","journal-title":"HIV Med"},{"key":"2026020904065362000_ciaf538-B16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1089\/aid.2012.0292","article-title":"Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK study","volume":"29","author":"Squires","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026020904065362000_ciaf538-B17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/0956462416679550","article-title":"Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: real-life analysis of the German \u2018WIP\u2019 cohort","volume":"28","author":"Naumann","year":"2017","journal-title":"Int J STD AIDS"},{"key":"2026020904065362000_ciaf538-B18","doi-asserted-by":"crossref","first-page":"18579","DOI":"10.7448\/IAS.16.1.18579","article-title":"Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents","volume":"16","author":"Agwu","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"2026020904065362000_ciaf538-B19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/cid\/ciw213","article-title":"Meyer WA 3rd, et al; pediatric HIV\/AIDS cohort study (PHACS); antiretroviral drug resistance among children and youth in the United States with perinatal HIV","volume":"63","author":"Van Dyke","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026020904065362000_ciaf538-B20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jinf.2015.12.005","article-title":"Incidence and predictors of antiretroviral resistance in perinatally HIV-1 infected children and adolescents","volume":"72","author":"Contreras","year":"2016","journal-title":"J Infect"},{"key":"2026020904065362000_ciaf538-B21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/QAI.0000000000001525","article-title":"Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens","volume":"76","author":"Norwood","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026020904065362000_ciaf538-B22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"NAMSAL ANRS 12313 Study Group","year":"2019","journal-title":"N Engl J Med"},{"key":"2026020904065362000_ciaf538-B23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2026020904065362000_ciaf538-B24","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026020904065362000_ciaf538-B25","doi-asserted-by":"crossref","first-page":"101412","DOI":"10.1016\/j.eclinm.2022.101412","article-title":"Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy\u2014a systematic literature review and network meta-analysis","volume":"48","author":"Kanters","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026020904065362000_ciaf538-B26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12879-022-07091-1","article-title":"Effects of different integrase strand transfer inhibitors on body weight in patients with HIV\/AIDS: a network meta-analysis","volume":"22","author":"Bai","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2026020904065362000_ciaf538-B27","first-page":"537","article-title":"Preventing and diagnosing HIV-related comorbidities in adolescents","volume":"30","author":"Yusuf","year":"2022","journal-title":"Top Antivir Med"},{"key":"2026020904065362000_ciaf538-B28","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1097\/QAD.0000000000003892","article-title":"Agwu A; North American AIDS cohort collaboration on research and design (NA-ACCORD). incidence of non-AIDS defining comorbidities among young adults with perinatally acquired HIV in North America","volume":"38","author":"Haw","year":"2024","journal-title":"AIDS"},{"key":"2026020904065362000_ciaf538-B29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s13679-016-0190-2","article-title":"The health consequences of obesity in young adulthood","volume":"5","author":"Cheng","year":"2016","journal-title":"Curr Obes Rep"},{"key":"2026020904065362000_ciaf538-B30","article-title":"Weight gain among adolescents on dolutegravir: a real concern?","author":"Riscart","year":"2022","journal-title":"CROI"},{"key":"2026020904065362000_ciaf538-B31","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1097\/INF.0000000000003076","article-title":"Increase in body mass Index in children with HIV, switched to tenofovir alafenamide fumarate or dolutegravir containing antiretroviral regimens","volume":"40","author":"Yeoh","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"2026020904065362000_ciaf538-B32","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/hiv.13302","article-title":"No overall impact on body mass index for age change after dolutegravir initiation in a French paediatric cohort","volume":"23","author":"Frange","year":"2022","journal-title":"HIV Med"},{"key":"2026020904065362000_ciaf538-B33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/INF.0000000000003904","article-title":"Decreased hepatic steatosis in South African adolescents with perinatal HIV switching to dolutegravir-containing regimens","volume":"42","author":"Rose","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"2026020904065362000_ciaf538-B34","doi-asserted-by":"crossref","first-page":"ofab308","DOI":"10.1093\/ofid\/ofab308","article-title":"Rakhmanina NY; DC cohort executive committee. Integrase strand transfer inhibitors and weight gain in children and youth with perinatal human immunodeficiency virus in the DC cohort","volume":"8","author":"Koay","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026020904065362000_ciaf538-B35","doi-asserted-by":"crossref","first-page":"e580-e586","DOI":"10.1093\/cid\/ciaa1652","article-title":"Transition to dolutegravir is associated with an increase in the rate of body mass Index change in a cohort of virally suppressed adolescents","volume":"73","author":"Thivalapill","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026020904065362000_ciaf538-B36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12887-023-04143-6","article-title":"Weight gain and BMI in virally suppressed children on antiretroviral therapy with specific reference to dolutegravir","volume":"23","author":"Belfrage","year":"2023","journal-title":"BMC Pediatr"},{"key":"2026020904065362000_ciaf538-B37","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3390\/microorganisms8060864","article-title":"Switching to integrase inhibitors unlinked to weight increase in perinatally HIV-infected young adults and adolescents: a 10-year observational study","volume":"8","author":"Taramasso","year":"2020","journal-title":"Microorganisms"},{"key":"2026020904065362000_ciaf538-B38","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/INF.0000000000000848","article-title":"P1093 study team. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: forty-eight-week results from IMPAACT P1093","volume":"34","author":"Viani","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2026020904065362000_ciaf538-B39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0000000000002119","article-title":"Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors","volume":"33","author":"Gelpi","year":"2019","journal-title":"AIDS"},{"key":"2026020904065362000_ciaf538-B40","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/CIRCULATIONAHA.113.001978","article-title":"Pediatric HIV\/AIDS Cohort Study (PHACS). Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus","volume":"129","author":"Patel","year":"2014","journal-title":"Circulation"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf538\/64824965\/ciaf538.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/1\/e78\/64824965\/ciaf538.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/1\/e78\/64824965\/ciaf538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:07:04Z","timestamp":1770628024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/1\/e78\/8293966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2026,2,9]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf538","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,15]]},"published":{"date-parts":[[2025,10,22]]}}}